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Development and Characterization
of Nonpeptidic Small Molecule Inhibitors
of the XIAP/Caspase-3 Interaction
some of which are now being tested in clinical trials for
cancer treatment [5].
Among the IAP family members, the X chromosome-
linked inhibitor of apoptosis protein (XIAP) is regarded
as the most potent suppressor of cell death [6]. XIAP
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La Jolla, California 92037 consists of four major domains: BIR1, BIR2, BIR3, and
RING. At least one explanation for the versatile suppres-2 Genomics Institute
of the Novartis Research Foundation sion of cell death exhibited by XIAP resides in its ability
to inhibit caspases [3, 4]. More specifically, the BIR1-210675 John Jay Hopkins Drive
San Diego, California 92121 region of XIAP is a potent and specific inhibitor of cas-
pases-3 and -7, whereas BIR3 is specific for caspase-9
[7–9, 10]. Besides inhibiting caspases, XIAP has been
reported to induce cell-cycle arrest and active signal
Summary transduction pathways mediated by NFB, c-Jun amino-
terminal kinase, and SMAD-dependent transcription [3].
Elevated expression of inhibitor of apoptosis protein Posttranslationally, XIAP can be regulated by inhibi-
(IAP) family members in various types of cancers is tory proteins, such as Smac (second mitochondrial acti-
thought to provide a survival advantage to these cells. vator of caspases) [11]. Following appropriate apoptotic
Thus, antiapoptotic functions of IAPs, and their poten- stimuli, Smac is released from the mitochondria to dis-
tial as novel anticancer targets have attracted consid- rupt XIAP-caspase complexes. Caspases, once liber-
erable interest. Among the IAPs, the X chromosome- ated from XIAP inhibition, execute apoptosis by the spe-
linked inhibitor of apoptosis protein (XIAP) is regarded cific proteolysis of a wide variety of substrates ultimately
as the most potent suppressor of mammalian apopto- leading to cell death. The molecular details of the Smac-
sis through direct binding and inhibition of caspases. XIAP interaction have recently been revealed by the
A high-throughput biochemical screen of a combina- X-ray cocrystal structures of the XIAP-BIR3 region in
torial chemical library led to the discovery of a novel complex with Smac-derived peptides [12, 13]. These
nonpeptidic small molecule that has the ability to dis- structures, in combination with a recent report describ-
rupt the XIAP/caspase-3 interaction. The activity of ing the mechanisms of caspase-9 activation, have pro-
this nonpeptidic small molecule inhibitor of the XIAP/ vided insights into the mechanism by which Smac
caspase-3 interaction has been characterized both in blocks BIR3-mediated inhibition of caspase-9 [14]. How-
vitro and in cells. Molecules of this type can be used ever, similar structural studies addressing the role of
to conditionally inhibit the cellular function of XIAP full-length Smac in the relief of XIAP-BIR1-2-mediated
and may provide insights into the development of ther- inhibition of caspases-3 and -7 have yet to be described
apeutic agents that act by modulating apoptotic [7–9]. Smac-derived peptides have been reported to
pathways. bind the caspase-9 binding site on XIAP-BIR3 [15]; they
have also been shown to facilitate activation of procas-
pase-3 [16], although it is unclear if this results fromIntroduction
direct inhibition of XIAP binding to active caspase-3.
Since both the extrinsic and intrinsic apoptosis path-The ability to evade cell death through suppression of
ways require the executioner caspase-3, molecular toolsapoptosis is considered one of the essential hallmarks of
that modulate the interaction of caspase-3/XIAP shouldhuman cancers [1]. Apoptosis pathways in mammalian
be useful probes of the cellular functions of these pro-cells are divided into two categories: extrinsic and intrin-
teins. Such molecules could ultimately lead to antican-sic. While the extrinsic pathway is activated by cellular
cer therapies. Here, we describe the identification of adeath receptor-ligand interactions, the intrinsic pathway
nonpeptidic small molecule inhibitor of the caspase-3/is regulated through the mitochondria. Both pathways
XIAP interaction from a combinatorial chemical libraryultimately activate effector caspases (cysteinyl aspar-
using high-throughput screening. Furthermore, this in-tate-specific proteases), mainly caspase-3 and -7 to in-
hibitor was used to probe the function of XIAP in relevantduce apoptosis [2–4]. Suppression of these effector cas-
biochemical and cell-based tumor models.pases by misregulation of both pro- and antiapoptotic
proteins provides a survival advantage during onco-
genesis and facilitates resistance to chemotherapies.
Discovery and Synthesis of Small MoleculeAmong the antiapoptotic proteins that have been impli-
Inhibitors of XIAP/Caspase-3cated in this process is the inhibitor of apoptosis protein
Since active caspase-3 is efficiently inhibited by XIAP,(IAP) family [2–4]. Characterization of antiapoptotic pro-
the enzymatic activity of caspase-3 was used to screenteins, including IAPs, has resulted in the development
for inhibitors of the XIAP/caspase-3 interaction (Figureof new strategies targeting cancer survival mechanisms,
1A). Recombinant XIAP was incubated with compounds
in buffer containing fluorogenic caspase-3 substrate
(Ac-DEVD-afc), followed by caspase-3 addition. Mole-*Correspondence: deveraux@gnf.org (Q.L.D.), schutlz@gnf.org (P.G.S.)
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Figure 1. XIAP/Caspase-3 Activity Assay
(A) Small molecules were coincubated with
caspase-3 and XIAP in a high-throughput
screening (HTS) format, and fluorescence in-
tensities were plotted on a graph for each
of the compound tested. The fluorescence
intensity inversely correlates with inhibition
of XIAP on caspase-3.
(B) Caspase-3 alone causes an increase in
fluorescence over time as the Ac-DEVD-afc
substrates are being hydrolyzed. Coincuba-
tion with XIAP decreases the fluorescence
intensity due to caspase-3 inhibition. As an
example, addition of TWX006 at 1, 3, 9, and
25 M concentration resulted in a dose-
dependent increase in fluorescence signal.
cules that block XIAP/caspase-3 complex formation are room temperature with a polystyrene carbamate resin
[18]. The initial loading of the resin is approximately 1.0expected to restore caspase activity, which is measured
by cleavage of the fluorogenic peptide substrate (Figure mmol/g. The second fragment (Figure 2B, 2-A to 2-P)
can be substituted with a variety of aryl sulfonyl and1B) [17]. Screening a library containing approximately
160,000 compounds in a 1536-well format identified sev- carbonyl chlorides and is introduced by a condensation
reaction with quantitative conversion. Depending on theeral moderately active small molecules. Control assays
confirmed that these molecules do not influence cas- nature of the aryl substituents, the third building block,
which again is chosen from diamine linkers (Figure 2B,pase-3 activity in the absence of XIAP (data not shown).
In addition, it was observed that longer preincubation 3-A to 3-E), can be introduced by two different strate-
gies. If the aryl substituent X is the more electron-with-of compounds with XIAP resulted in faster activation
of caspase relative to preincubation with caspase-3, drawing fluorine, the diamine can be incorporated by a
SNAr reaction by heating the starting resin in N-methyl-suggesting that these molecules may bind to XIAP in-
stead of caspase-3. Unfortunately, the inhibitors identi- pyrrolidine (NMP) at 80C in the presence of the diamine
for 24 hr. This reaction is complicated by the dimeriza-fied from the primary screen exhibited poor solubility in
aqueous solution. At 20 M concentration in aqueous tion of the molecule on solid support, as one diamine
molecule contains two nucleophilic ends. Nevertheless,media, most active small molecules precipitated over-
night; therefore, their usefulness in cell models is limited. by using large excess of the diamine (20 equivalents),
dimerized side product is reduced to less than 15%. If XHence, a small focused library of molecules (named
TWX) based on the original hits was synthesized with is bromine or iodine, a palladium cross-coupling method
was used with Pd2(dba)3 as the catalyst and 2-(di-tert-the aim of finding XIAP inhibitors with improved physical
properties and/or affinity, which are more suitable for butylphosphino)biphenyl as the ligand in the presence
of potassium tert-butoxide in DMF at 80C [19]. Again,studies in cellular systems.
The TWX molecular scaffold can be broken down into the dimerization problem was suppressed by adding
excess diamine, and the yields of the desired productfour fragments, each of which can be substituted by a
series of diverse building blocks with solid-phase or- were typically in the range of 75%–90%. The fourth frag-
ment consisted of a variety of substituted carbonyl chlo-ganic synthesis (Figure 2A). The first fragment (Figures
2B, 1-A to 1-D), which can be substituted by any of a rides, sulfonyl chorides, isocyanates, and isothiocya-
nates (Figure 2B, 4-A to 4-V) that were introduced by aseries of diamine linkers, is incorporated by condensa-
tion of the amine in N,N-dimethylformamide (DMF) at final condensation reaction with quantitative conver-
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sions. The molecules were cleaved from the resin by inactive compound TWX041 (which has no detectable
activity at 100 m concentration) did not block associa-treatment with 50% trifluoroacetic acid in dichlorometh-
ane for 2 hr at room temperature, which typically re- tion of BIR1-2 and caspase-3 in these assays. These
results indicate that TWX024 specifically disrupts thesulted in compounds of 70%–90% purity as shown by
LCMS. All compounds were further purified by HPLC binding of XIAP to caspase-3.
using a C18 column with a 10 min gradient of 10%–95%
acetonitrile/water and used as 10 mM DMSO stock solu- TWX Synergizes with an Agonistic Anti-DR5
tions. Based on the initial resin loading, the overall puri- Antibody in HCT116 Bax/ Cells
fied yields were between 30% and 60%. This collection The induction of apoptosis through the tumor-specific
of analogs was screened in duplicate in the caspase TRAIL death receptor (extrinsic) pathway is a promising
activity assay. approach for cancer therapy [20]. Similar to CD95, TRAIL
From this small sublibrary, several derivatives were initiates apoptosis through the death receptor pathway
found to have significant activity, including TWX006 by activating caspase-8 and then caspase-3. However,
(IC50  10 M) and TWX024 (IC50  25 M) (Figure 2C). recent evidence reveals that TRAIL-mediated apopto-
For comparison, the N7-Smac peptide inhibits the XIAP/ sis is dependent upon the proapoptotic Bcl-2 family
caspase-3 interaction with an IC50 greater than 75 M. member Bax, which lies on the mitochondria (intrinsic)
Similar results were obtained using XIAP-inhibited cas- pathway [21, 22]. Upon stimulation by TRAIL, caspase-8
pase-7 (data not shown). TWX024, while slightly less activates not only caspase-3 but also Bid, which subse-
potent than TWX006, exhibits higher solubility in aque- quently activates Bax on the outer mitochondria mem-
ous media and was used for cellular studies. brane. Bax promotes the release of Smac, which binds
To test whether these molecules can inhibit the func- to XIAP, thereby relieving the inhibition of caspase-9
tion of XIAP in a more biologically relevant context, the and caspase-3. Without functional Bax, caspase-3 is
cellular activity of TWX024 compound was examined in inhibited by XIAP, resulting in reduced apoptosis even in
the 293 cell line (Figure 3). Ectopic expression of the the presence of death receptor stimulation. This cross-
CD95 death receptor (CD95) initiates the extrinsic apo- signaling between the two pathways is thought to be
ptosis pathway, providing a death stimulus that resulted an amplification mechanism evolved to enhance the
in more than 50% of transfected 293 cells undergoing apoptosis signal initiated by the death receptor. How-
apoptosis after 24 hr. Apoptotic 293 cells are detected ever, in a number of human tumors (e.g., tumors exhib-
by morphological features such as cells rounding up, iting DNA mismatch repair [MMR] deficiencies) Bax is
detachment, and production of apoptotic bodies (Figure often the target of mutation and inactivation, rendering
3B). Coexpression of XIAP with CD95 has previously these cells TRAIL resistant [22].
been shown to block apoptosis [10]. Consistent with Here, we ask if the TWX024 XIAP inhibitor could re-
this report, cotransfection of XIAP with CD95 led to store TRAIL sensitivity in a Bax-deficient HCT116 cell
survival in 95% of the transfected cells (Figure 3C), indi- line [21]. HCT116 Bax/ and Bax/ cell lines were
cating that XIAP is blocking apoptosis by inhibiting cas- treated with agonistic anti-DR5 antibodies, which mimic
pase-3. The addition of TWX024 to 293 cells cotrans- the effect of the TRAIL ligand and selectively activate the
fected with XIAP and CD95 significantly reversed this TRAIL-DR5 receptor (our unpublished data). Consistent
phenomenon and restored CD95-induced apopto- with the reported data, Bax/ cells were significantly
sis—over 50% of the transfected cells underwent apo- less sensitive to treatment with this death stimulus (80%
ptosis in the presence of 25 M TWX024 (Figure 3D). cell viability) in contrast to Bax/ cells (30% cell viabil-
Treatment with 40 M of TWX024 alone did not induce ity) (Figure 5). However, cotreatment with anti-DR5 and
apoptosis (Figure 3E). These transient transfection 10M of TWX024, but not TWX041, caused a synergistic
assays provide direct evidence that TWX024 retains its cell death effect (50% cell viability) in Bax-deficient
ability to relieve the inhibition of XIAP on caspase-3 in HCT116 cells. Hence, these data strongly suggest that
cells. TWX024 substituted for the function of endogenous
Smac by inhibiting the XIAP/caspase-3 interaction,
thereby facilitating caspase activation and apoptosis.TWX024 Disrupts the XIAP/Caspase-3 Interaction
Interestingly, treatment with TWX024 alone did notA series of coprecipitation experiments were performed
cause elevated death in HCT116 cells. It is possible thatto confirm the ability of TWX analogs to disrupt the
without a proapoptotic signal, simply removing the XIAPinteraction between XIAP and active caspase-3 (Figure
inhibition on caspase-3 does not trigger significant apo-4). Recombinant GST-tagged BIR1-2 was used to “pull
ptosis because most caspase-3 exists in the inactivedown” caspase-3, and the complex was captured with
procaspase form. Therefore, unless there is an apopto-GST-coated sepharose resins. Caspase-3 itself was not
sis signal to mature procaspase-3, relief of XIAP inhibi-pulled down by GST-sepharose because it lacks affinity
tion alone does not promote apoptosis. Taken together,for the resins. After a series of washing to remove any
the synergistic effect of TRAIL-DR5 agonists andnonspecifically bound proteins, the proteins retained by
TWX024 can be extended to cells having other proapo-the resins were separated on SDS-PAGE. The presence
ptotic defects in the mitochondrial release of Smac.of caspase-3 was revealed by Western blot analysis
using polyclonal anti-caspase-3 antibody. When 25 M
of TWX024 was coincubated with GST-BIR1-2 and cas- Structural-Activity Relationship and Modeling
An analysis of the structure-activity relationship (SAR)pase-3 in PBS buffer, no caspase-3 was retained by the
resins as shown by Western blot. However, 25 M of the data generated from screening the focused library pro-
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Figure 2. Continued on next page.
vided insights into the structural features necessary for sulfonyl groups had increased activity relative to car-
bonyl groups when substituted in the second frag-inhibitor activity (Figure 2C). The flexible acyclic di-
amines had higher activity than cyclic diamines when ment—molecules derived from the aryl acid chlorides
2-D and 2-E have essentially no activity relative to thosesubstituted in fragment one. Ethyl substituents on either
nitrogen led to increased activity relative to methyl sub- containing the aryl sulfonamide 2-A and 2-B, suggesting
that proper positioning of the H bond donor oxygen isstitution (propyl or larger substituents were not tested),
indicating that hydrophobicity is critical for activity. Aryl critical for binding. The second and third fragments can
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Figure 2. Chemical Synthesis of TWX Analogs
(A) Synthetic scheme for TWX analogs.
(B) Diversity elements used in the synthesis of TWX analogs.
(C) Structures and activities of selected TWX analogs. Plus marks () represent the percentage of XIAP inhibition at 20 M of small molecule:
, 80%–100%; , 60%–79%; , 40%–59%; , 20%–39%; , 0%–19%. These compounds do not affect caspase-3 activity
in the absence of XIAP.
be para or meta linked, but ortho linkage (2-C) decreases phatic chain (4-J) also has poor activity. The ureido
group (4-Q) improved the solubility of the molecule (e.g.,activity dramatically. Addition of an ortho-fluorine atom
on the aromatic ring of fragment two increases activity; TWX024), although amide (4-C) serves as the best link-
age between the third and fourth fragment. Attempts2-G was the optimal second fragment examined. The
more rigid fragments (3-B and 3-C) and shorter frag- to make truncated versions in which N- or C-terminal
fragments were deleted resulted in a loss of activity.ments (3-D and 3-E) both have considerably lower activ-
ity than 3-A. The scaffold can tolerate a wide variety of This SAR data was used together with molecular mod-
els of the interaction between TWX006 and XIAP to beginlarge, hydrophobic groups in the fourth fragment, as
4-A to 4-D all have similar activities. Smaller, more polar to gain insights into how TWX006 might inhibit the inter-
action of XIAP with caspase-3. Initially, the optimal bind-groups result in lower activities, which implies fragment
four occupies a large hydrophobic pocket. A long ali- ing site for TWX006 was searched on available XIAP
Chemistry & Biology
764
Figure 3. 293 Cell Transfection Assays
(A) Cells transfected with GFP as a positive control exhibit normal cell morphology.
(B) Over 50% of cells transfected with pcDNA3-CD95 underwent apoptosis, as indicated by the production of apoptotic bodies.
(C) Transfection of pcDNA3-XIAP along with pcDNA3-CD95 blocked apoptosis in 95% of transfected cells.
(D) Addition of TWX024 (25 M) to cells transfected with pcDNA3-CD95 and pcDNA3-XIAP induced apoptosis in up to 50% of transfected
cells.
(E) Treatment with TWX024 (40 M) alone has no apoptosis-inducing effect.
and caspase-3 structures (1I3O.pdb) using Glide (ver- lowers the binding affinity possibly by disrupting the
optimal H bond angle. In the docked complex, TWX006sion 2.0). Once confined to a specific binding surface,
twists through a hydrophobic groove of BIR2. A longthe small molecule binding conformation was optimized
and flexible dipiperidine moiety (3-A) is necessary tousing a mixed Monte Carlo Mulitple Minimum (MCMM)
avoid a steric clash with a side chain protruding into thealgorithm provided by MacroModel (version 7.0). The
groove, again consistent with the SAR data. The modelresultant model predicts that TWX006 occupies the
places the fourth fragment of the inhibitor into the hy-linker region between BIR1 and BIR2 of XIAP (Figure 6);
drophobic site occupied by residues of caspase-3 inthe same region caspase-3 was shown to bind in the
the corresponding caspase-3/XIAP complex. It is likelyprevious crystallographic studies [7–9]. The key features
that fragment 4-C interferes with caspases-3 binding byof this model are supported by the SAR generated from
occupying the binding surface composed of residuesthe focused library of TWX analogs.
Ser 150, Tyr 154, Cys 203, and Phe 228 of BIR2. InThe modeling experiments suggest that the terminal-
the BIR2/caspase-3 complex, this hydrophobic regionamino group of fragment 1-A forms H bonds with the
is occupied by caspase-3 residue Met 316, whose back-sidechains of Asp 214 and Glu 219 of BIR2, and the
bone oxygen H bonds to the backbone nitrogen of Asnsulfonyl oxygen of element 2-G makes a H bond with
226 of BIR2. In the TWX006/caspase-3 complex thethe backbone nitrogen of Lys 208 of BIR2. Switch-
backbone nitrogen of Asn 226 of BIR2 is H bondeding the sulfonyl to a carbonyl for fragment two (2-D)
with carbonyl oxygen of fragment 4-C. The experimental
observation that a bulkier fourth diversity element has
higher activity is consistent with the proposed binding
model of TWX006, as it predicts better interactions with
the hydrophobic region at the caspases-3 binding site.
The flexibility and length of the third diversity element
is also critical, since the model suggests that rigid and/
or shorter moieties will reduce the extension of the mole-
cule into the caspase-3 binding region. TWX041 does
not have the length required for extension into the cas-
pases-3 binding interface and therefore has reduced
activity. The observation that TWX also relieves BIR2
inhibition on caspase-7 suggests that the same mecha-
nism of protein complex disruption can also be impliedFigure 4. GST-BIR1-2 Coprecipitation Experiments
with XIAP/caspase-7 given the structural similarity ofSDS-PAGE followed by caspase-3 Western blot was performed with
caspase-3 and -7.the proteins retained by GST-sepharose resins. Recombinant active
caspase-3 was loaded as a positive control (lane 1). Active cas- Based on the predicted TWX binding model and SAR
pase-3 lacking a GST tag was not retained by GST-sepharose (lane data, active TWX analogs disrupt the XIAP/caspase-3
2). However, coincubation of caspase-3 along with GST-BIR1-2 re- complex by directly occupying the protein-protein inter-
sulted in the coprecipitation of caspase-3 (lane 3). Addition of
action interface (the linker region between BIR1 andTWX024 at 25 M prevented/disrupted the binding of GST-BIR1-2
BIR2). Full-length Smac protein, an endogenously ex-to caspase-3 (lane 4). Lower concentrations of TWX024 (10 M) or
pressed inhibitor of the XIAP/caspase-3 interaction,TWX041 (25 M) did not affect the binding of caspase-3 to GST-
BIR1-2 (lanes 5 and 6). binds to BIR2 and extends itself into the linker region,
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peptidomimetics for developing small molecule drugs
that target the XIAP/caspase-3 interaction.
Significance
High-throughput screening and parallel solid-phase
organic synthesis were used to rapidly identify a series
of small molecule inhibitors of the caspase-3/XIAP
interaction. The TWX compounds represent the first
generation of small molecules capable of interfering
with XIAP’s ability to inhibit executioner caspases-3
and -7. These compounds were employed to probe
Figure 5. TWX Synergy with Agonistic Antibodies Specific for the XIAP function in tumor cells lines and to show that
TRAIL Death Receptor DR5
they could be used to “bypass” the apoptosis block
HCT116 Bax/ and HCT Bax/ cells were treated with anti-DR5 resulting from the loss of the proapoptotic Bcl-2 familywith or without 10 M TWX. Bax/ cells were sensitive to anti-DR5
member Bax in a colon carcinoma cell line. Since manytreatment, but Bax/ cells were not. Addition of TWX024, but not
tumor cells evade apoptosis by dampening the intrin-TWX041, sensitized Bax/ cells to the proapoptotic effect of anti-
DR5. As a control, TWX024 alone has relatively low toxicity in sic mitochondrial apoptosis pathway, these com-
HCT116/ cells. pounds will be useful for further elucidation of these
tumor cell survival strategies and may facilitate devel-
opment of therapeutically useful agents that target
thereby preventing the binding of caspase-3 through a XIAP function in relevant carcinomas.
buttress effect [9]. Although N7-Smac peptide may have
binding affinity for BIR2, it lacks the sterical bulkiness Experimental Procedures
required to hinder binding of caspase-3 to the linker
High-Throughput Screening and Caspase Activity Assaysregion. The inhibition of caspase-9 by XIAP operates
Caspase activities were assayed as previously described [23] atthrough a different mechanism [14], which implies that
37C in 6 l caspase buffer (50 mM HEPES, pH 7.4, 100 mM NaCl,the Smac-mediated relief of caspase-9 inhibition must
10% sucrose, 1 mM EDTA, 0.1% CHAPS). The high-throughput
also be different than that of caspase-3. Smac protein screens were carried out in 1536-well formats. Recombinant XIAP-
displaces XIAP from caspase-9 by directly competing BIR2 (5 l, 21.3 nM) in caspase buffer (with 296 M Ac-DEVD-afc;
Calbiochem, San Diego, CA) was added to the wells, followed byfor the BIR3 domain [12, 13]. Hence, N-terminal Smac
addition of compound in neat DMSO (final compound concentrationpeptide and derivatives retain the XIAP inhibitory activity
about 10 M). The mixture was incubated at room temperature foron caspase-9 because of their high affinity for the BIR3
20 min. Caspase-3 (1l, 12.5 nM) in caspase buffer (with 10 mM DTT)domain [10], but cannot also disrupt the XIAP/caspase-3
was added to each well. An initial fluorescence reading (Acquest
interaction. This suggests that compounds such as LJL Biosystems, Molecular Device Corporation, Sunnyvale, CA) was
TWX006 or TWX024, which bind directly to the linker measured followed by a final reading after 1 hr incubation. Activity
was measured as the difference in signal between the final readregion between BIR1 and BIR2, are better than Smac
Figure 6. Computational Modeling of TWX
Binding to XIAP
A computational model of TWX binding to
XIAP-BIR2. The TWX binding surface shares
a significant overlap with the caspase-3 bind-
ing surface. TWX006 (green) makes critical H
bond contacts with Asp 214, Glu 219, and Lys
208 of BIR2. The fourth fragment of TWX006
occupies the hydrophobic pocket formed by
Asn 226, Tyr 154, and Phe 228 of BIR2, ex-
tending into the caspase-3 binding region.
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and the initial read. Postscreening IC50 tests on selected compounds (with 10% FBS) was added. Compounds were also added at this
time. Cells were imaged with a fluorescence microscope 24 hr afterwere carried out in 384-well formats in 40 l caspase buffer using
a continuous reading fluorometer (Molecular Devices Spectramax, addition of the compounds. HCT116 Bax/ and Bax/ cells were
cultured in RPMI supplemented with 10% FBS. One day beforeMolecular Device). The assay procedure was the same except that
fluorescence measurements were taken in the kinetic mode. addition of anti-DR5 and TWX compound, cells were split and plated
in 96-well tissue culture plates, each containing 100 l of cells at
1  105 cells/ml. Anti-DR5 (2 g/l) and compounds were addedChemistry
to the wells as described in Figure 5. The MTT assay, which is aAll reagents and solvents were purchased from Sigma/Aldrich (Mil-
colorimetric assay based on the ability of viable cells to reduce awaukee, WI); the palladium catalysts and ligands were purchased
soluble yellow tetrazolium salt (MTT) to blue formazan crystals, wasfrom Strem Chemicals (Newburyport, MA). Carbamate resin was
used to determine the number of viable cells.made in bulk quantity according to reported literature [18]. For each
TWX analog, 100–500 mg of carbamate resin (0.8 mmol/g) was mixed
with the first diversity element (20 equivalents [eq.]) dissolved in Pull-Down Assay and Western Blot Analysis
N,N-dimethylformamide (DMF) and shaken at room temperature Glutathione-sepharose resins (20l) were incubated with caspase-3
overnight. The resins were then washed successively with dichloro- (1 nM), XIAP-BIR1-2 or XIAP-BIR3-RING (50 nM), and TWX (in accor-
methane (DCM) and DMF for four times and dried under vacuum dance with Figure 3) in 60l PBS at 4C for 30 min. The samples were
overnight. Subsequently, the resins were suspended in DCM and centrifuged at 1000 rpm for 5 min. The supernatant was removed and
treated with the second diversity element (5 eq.), collidine (5 eq.), the beads were washed three times with 100 l PBS. SDS sample
and shaken at room temperature overnight, followed by washing loading buffer (20 l) was added to the beads and heated at 95C
and drying. For X F, the third diversity element (20 eq.) was heated for 5 min. Each sample was subsequently separated under reducing
with the resins in N-methylpyrrolidine at 80C for 24 hr. For X  Br conditions on 10%–20% gradient SDS-polyacrylamide gels. After
or I, the third diversity element (10 eq.) was mixed with the resins transfer to nitrocellulose membranes, the membranes were incu-
along with Pd2dba3 (0.15 eq.), ligand (0.6 eq.), potassium tert-butox- bated for 1 hr in 10% nonfat milk powder followed by 1 hr incubation
ide (10 eq.), and DMF and heated to 80C under argon atmosphere with the rabbit anti-caspase3 polyclonal antibody (1:1000; Phar-
for 18 hr. After washing and drying, the resins were suspended in mingen, San Diego, CA). The membrane was washed fives times
DCM and treated with the fourth diversity element (5 eq.), collidine with PBS/0.05% Tween, incubated with anti-rabbit peroxidase-con-
(5 eq.), and shaken at room temperature overnight. The resins were jugated affinity-purified secondary antibody (1:5000; Biorad, Her-
wash and dried. Cleavage is mediated by treatment of the resin cules, CA) for 30 min, washed again five times, developed using
with a cocktail of TFA/DCM/Me2S/H2O (45:45:5:5) for 2 hr at room enhanced chemiluminescence (ECL; Amersham, Piscataway, NJ),
temperature. The liquid was drained and the resins were washed and exposed to Kodak Biomax films.
one time with DCM. The combined liquid was concentrated and
subjected to HPLC using a C18 reverse column and eluting with
Virtual Modeling5%–95% acetonitrile in water gradient. The purified compounds
The virtual model was constructed using two computational soft-were concentrated and typical yields are between 30% and 60%
wares (Glide and MacroModel) and based on the published crystalrelative to initial resin loading. All compound were dissolved as 10
structure of XIAP/caspase-3 that can be downloaded from the Pro-mM stock solution for assays. Purity of compounds was assessed
tein Data Bank (1I3O.pdb). Flexible ligand docking was performedby reverse-phase liquid chromatography mass spectrometry (4 min
with Glide (version 2.0; Schrodinger Inc., Portland, OR). For the gridselution using 5%–95% acetonitrile in water) with an UV detector
calculation, the van der Waals radii of nonpolar protein atoms wereat   255 nm and an electrospray ionization source. TWX006:
scaled by a factor of 0.9. The enclosing box for ligand docking wasC39H53FN4O3S calc’d 676.4, found [MH] 677.4; TWX024: C39H54
centered on the Smac binding pocket and was 34 A˚ in size alongFN5O3S calc’d 691.4, found [MH] 692.4; TWX041 C30H37FN4O3S
each dimension. Electrostatic interactions were calculated with acalc’d 552.3, found [MH] 553.3.
distance-dependent dielectric constant 2r. The van der Waals radiiTWX024: 1H NMR (500 MHz, CDCl3) 	 8.68 (br, 2H), 7.39–7.49 (m,
of nonpolar ligand atoms were scaled by a factor of 0.8. The maxi-5H), 7.28–7.31 (m, 3H), 7.18 (t, J  7.8 Hz, 1H), 6.97 (s, 1H), 6.45 (d,
mum number of poses selected for refinement was 5000, and theJ  9.1 Hz, 1H), 6.37 (d, J  14.7 Hz, 1H), 3.96 (d, J  12.9, 2H),
maximum number of refined poses selected final minimization and3.65 (d, J  12.6, 2H), 3.33 (s, 1H), 3.18 (m, 2H), 3.07 (q, J  7.1 Hz,
scoring was set at 400. Flexible protein/ligand docking was per-2H), 2.86–2.93 (m, 4H), 2.73 (t, J  12.4 Hz, 4H), 1.82 (m, 2H), 1.62
formed using the mixed Monte Carlo Multiple Minimum (MCMM)/(t, J  14.3 Hz, 4H), 1.32 (m, 2H), 0.99–1.20 (m, 12H), 0.92 (t, J 
LLMOD (Large Scale LowMode) conformational search strategy7.2 Hz, 3H). 13C NMR (500 MHz, CDCl3) 	 161.6, 159.1, 155.6, 140.7,
available in MacroModel (version 7.0; Schrodinger Inc.). During the138.9, 135.7, 132.0, 128.8, 127.4, 126.8, 120.7, 113.4, 113.2, 108.9,
LLMOD structural perturbation and subsequent minimization, seven101.2, 47.8, 44.8, 44.35, 44.32, 43.3, 43.0, 36.6, 36.5, 35.9, 35.6, 32.2,
protein residues were allowed to move freely: Tyr 154, Leu 207, Trp31.6, 25.4, 23.6, 13.7, 11.2.
210, His 223, Phe 224, Asn 226, and Phe 228. The remaining residues
were not allowed to move; however, their electrostatic and van derProteins Expression and Purification
Waals interactions with moving atoms was included in the calcu-The GST fusion proteins XIAP-BIR1-2 and XIAP-BIR3-RING were
lation. The inhibitor TWX006 was allowed to move freely duringprepared as previously described from the soluble fraction upon
the LLMOD step and subsequent minimization. In order to initiate theinduction with 0.4 mM IPTG at 30C for 3–20 hr and then purified
MCMM/LLMOD search the TWX006 inhibitor was placed into theby glutathione-sepharose affinity chromatography [6]. Recombinant
receptor in the orientation/conformation derived from the dockingcaspase-3 was a kind gift from G. Salvesen (The Burnham Institute,
by Glide. A 20,000 step search was conducted, which requiredSan Diego, CA).
148,500 CPU seconds on a single XEON processor. A 30 kJ/mol
window contained 130 unique structures and the global energy mini-Cell Culture, Transfection, and Cytotoxicity Assays
mum was found 33 times during the conformational search. The293 cells were cultured in Dulbecco’s modified Eagles medium
rmsd value between heavy atoms of freely moving residues of initial(DMEM) supplemented with 10% fetal bovine serum (FBS). One day
and global minimum conformations was 0.49 A˚.before transfection, the 293 cells were split and plated in 12-well
tissue culture plates, each well containing 1 ml of cells at 8  104
cells/ml. Transfections were carried out with a Fugene to DNA ratio Acknowledgments
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